NDRA ENDRA Life Sciences Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1681682 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY27.0%
TTM EPS YoY-126.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-217.7%
ROA-134.7%
ROIC (approx.)-360.8%
Asset turnover—
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio7.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $1.85M | $3.19M | $5.00M | $6.55M | $5.48M |
| SG&A expense | $3.72M | $7.06M | $4.70M | $5.17M | $4.94M |
| Operating income | -$5.76M | -$10.82M | -$10.52M | -$13.16M | -$11.50M |
| Pretax income | -$7.03M | -$11.51M | -$10.06M | -$13.18M | -$11.55M |
| Income tax | — | $0 | $0 | $0 | $0 |
| Net income | -$7.03M | -$11.51M | -$10.06M | -$13.18M | -$11.23M |
| EBITDA | -$5.72M | -$10.77M | -$10.40M | -$13.06M | -$11.38M |
| EPS (basic) | -8.93 | -56.94 | — | -4.56 | -5.55 |
| EPS (diluted) | -8.93 | -56.94 | -2,766.85 | — | — |
| Weighted avg. shares (diluted) | 787,020 | 202,106 | 3,636 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $762,365 | $3.23M | $2.83M | $4.89M | $9.46M |
| Inventory | $0 | $0 | $2.62M | $2.64M | $1.28M |
| Current assets | $967,969 | $3.43M | $3.03M | $5.38M | $12.09M |
| PP&E, net | $42,516 | $69,281 | $111,782 | $235,655 | $131,130 |
| Total assets | $3.85M | $4.45M | $6.75M | $9.27M | $12.87M |
| Current liabilities | $750,956 | $605,230 | $903,095 | $1.70M | $1.54M |
| Short-term debt | — | $0 | $28,484 | $28,484 | — |
| Long-term debt | — | $0 | $0 | $0 | $546,631 |
| Total debt | — | $0 | $28,484 | $28,484 | $546,631 |
| Total liabilities | $1.59M | $1.89M | $1.10M | $2.07M | $2.09M |
| Shareholders' equity | $2.26M | $2.56M | $5.66M | $7.20M | $10.78M |
| Net debt | — | -$3.23M | -$2.81M | -$4.86M | -$8.91M |
| Shares outstanding | 1.18M | 536,908 | 5,937 | 3.17M | 2.13M |
| Cash flow statement | |||||
| Operating cash flow | -$5.18M | -$7.40M | -$9.55M | -$12.77M | -$11.12M |
| Capital expenditure | $17,280 | $16,000 | $33,884 | $202,577 | $45,000 |
| Free cash flow | -$5.20M | -$7.42M | -$9.58M | -$12.97M | -$11.17M |
| Investing cash flow | -$3.02M | -$12,796 | -$24,721 | -$202,577 | -$45,000 |
| Financing cash flow | $5.73M | $7.81M | $7.52M | $8.40M | $13.40M |
| Depreciation & amortization | $44,045 | $46,489 | $123,726 | $96,661 | $116,238 |
| Stock-based compensation | $329,409 | $571,924 | $996,430 | $1.20M | $1.44M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.